

Technology Appraisal Committee D Interests Register

Topic: Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3852]

Publication Date: 28 September 2022

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Ivan Koychev	Committee member	Non-financial professional	Ivan Koychev has concluded in collaboration with Roche as part of which they developed a digital solution for detecting cognitive deficits in healthy ageing adults.	N/A	25.04.2022	N/A	It was agreed his declaration would not prevent Ivan from participating in discussions of this appraisal
Dr Matt Bradley	Committee member	Financial	Dr Bradley holds shares in AstraZeneca, the manufacturer of an identified and participating comparator (Osimertinib).	N/A	13.04.2022	N/A	As a direct conflict it was agreed that Dr Bradley would not participate in discussions of this appraisal.
Dr Shobhit Bajjal	Clinical expert	Financial	Dr Bajjal has received honoraria from Roche for consultancy work and other pharma companies which are the subject of this appraisal.	N/A	13.09.2021	N/A	It was agreed his declaration would not prevent Dr Bajjal from providing expert advice to the committee.
Dr Yvonne Summers	Clinical expert	Financial	Dr Summers has participated in paid advisory work for Roche and other pharma companies which are the subject of this appraisal.	N/A	01.10.2021	N/A	It was agreed her declaration would not prevent Dr Summers from providing expert advice to the committee

